SCHEMBL4340489

SCHEMBL4340489

COc1ccc(-c2ccc(/C=N/NC(N)=S)o2)c(Cl)c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.69
MEN1 O00255 5/20 0.69
ALDH1A1 P00352 5/20 0.69
KDM4E B2RXH2 5/20 0.69
LMNA P02545 4/20 0.69
MAPT P10636 6/20 0.64
NPSR1 Q6W5P4 5/20 0.64
HPGD P15428 4/20 0.64
ALOX12 P18054 2/20 0.60
HTT P42858 1/20 0.58
MAPK1 P28482 1/20 0.58
PKM P14618 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
POLB P06746 1/20 0.55
MAOA P21397 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4340492 1.00 KMT2A (0.69) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4459538 0.88 MEN1 (0.58) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4459532 0.88 MEN1 (0.58) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4335641 0.85 MAPT (0.82) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4335636 0.85 MAPT (0.82) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4336149 0.81 MAPT (0.74) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4336150 0.81 MAPT (0.74) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4324469 0.80 MAPT (0.73) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4343385 0.80 ALDH1A1 (0.69) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4343380 0.80 ALDH1A1 (0.69) KMT2AMEN1ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KMT2A 3988/4885MEN1 4874/4885ALDH1A1 1459/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KMT2A 3714/4885MEN1 4872/4885ALDH1A1 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.